These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21638121)

  • 1. Vascular normalization: a real benefit?
    Ribatti D
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):275-8. PubMed ID: 21638121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF inhibitors in brain tumors.
    Brastianos PK; Batchelor TT
    Clin Adv Hematol Oncol; 2009 Nov; 7(11):753-60, 768. PubMed ID: 20075834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
    De Bock K; Cauwenberghs S; Carmeliet P
    Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Are antiangiogenic antibodies universal for solid tumor?].
    Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.
    Oku T; Tjuvajev JG; Miyagawa T; Sasajima T; Joshi A; Joshi R; Finn R; Claffey KP; Blasberg RG
    Cancer Res; 1998 Sep; 58(18):4185-92. PubMed ID: 9751633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.
    Yang AD; Bauer TW; Camp ER; Somcio R; Liu W; Fan F; Ellis LM
    Cancer; 2005 Apr; 103(8):1561-70. PubMed ID: 15754332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting vessels to treat hepatocellular carcinoma.
    Romanque P; Piguet AC; Dufour JF
    Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy: creating a unique "window" of opportunity.
    Lin MI; Sessa WC
    Cancer Cell; 2004 Dec; 6(6):529-31. PubMed ID: 15607955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
    Sato Y
    Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors.
    Wong H; Yau T; Man CW; Epstein RJ
    Acta Oncol; 2009; 48(8):1213-5. PubMed ID: 19863234
    [No Abstract]   [Full Text] [Related]  

  • 15. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis.
    Manalo KB; Choong PF; Dass CR
    Mol Carcinog; 2011 Feb; 50(2):67-72. PubMed ID: 21229603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the tumor vascular compartment to improve conventional cancer therapy.
    Feron O
    Trends Pharmacol Sci; 2004 Oct; 25(10):536-42. PubMed ID: 15380938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
    Kunnakkat S; Mathew M; Narayana A
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.